Enrolling

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

J2G-MC-JZJX -

The reason for this study is to see if the study drug, selpercatinib, compared to placebo, is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Non-Small Cell Lung Cancer
What the trial is testing?
Selpercatinib
Could I receive a Placebo?
Yes
Enrollment Goal
170
Trial Dates
Dec 20, 2021 - Aug 2032
How long will I be in the trial?
Participation could last up to three years.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have early-stage non-small cell lung cancer (NSCLC)

  • Participants must have already had (and recovered from) surgery or radiation

  • Participants must be in fair to good health

  • Participants must be willing to use highly effective birth control during the study

Participants Must Not:

  • Participants must not have another serious medical condition

  • Participants must not have disease that has spread

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources